Thyromimetic drugs are synthetic agonists of thethyroid hormone receptor's isoforms TR α1, TRα2, TRβ1, or TRβ2, mimicking some or all of the effects of endogenously producedthyroid hormones that regulatemetabolism.[1][2] Some thyromimetic drugs are selective for various of these receptors over others, enabling more targeted effects and reducing toxicity. Thyromimetics selective for TRβ—includingeprotirome,[3]sobetirome,[4]resmetirom,[5] and theprodrugVK2809—have been investigated for the treatment ofnon-alcoholic fatty liver disease,dyslipidemia, and other metabolic and neurodegenerative diseases.[3]
- ^Unnikrishnan, A. G.; Baruah, Manash; Kalra, Sanjay (December 2012)."Thyromimetics: What does the future hold?".Indian Journal of Endocrinology and Metabolism.16 (Suppl 2):S159–S161.doi:10.4103/2230-8210.104029.ISSN 2230-8210.PMC 3603016.PMID 23565368.
- ^Devereaux, Jordan; Ferrara, Skylar J.; Scanlan, Thomas S. (2018). "Quantification of Thyromimetic Sobetirome Concentration in Biological Tissue Samples".Thyroid Hormone Nuclear Receptor. Methods in Molecular Biology. Vol. 1801. Springer. pp. 193–206.doi:10.1007/978-1-4939-7902-8_16.ISBN 978-1-4939-7901-1.
- ^abSaponaro, Federica; Sestito, Simona; Runfola, Massimiliano; Rapposelli, Simona; Chiellini, Grazia (2020)."Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders".Frontiers in Medicine.7: 331.doi:10.3389/fmed.2020.00331.ISSN 2296-858X.PMC 7363807.PMID 32733906.
- ^Tancevski, Ivan; Demetz, Egon; Eller, Philipp (1 January 2011)."Sobetirome: A Selective Thyromimetic for the Treatment of Dyslipidemia".Recent Patents on Cardiovascular Drug Discovery.6 (1):16–19.doi:10.2174/157489011794578473.
- ^Alkhouri, Naim (1 February 2020)."Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)".Expert Opinion on Investigational Drugs.29 (2):99–101.doi:10.1080/13543784.2020.1708899.ISSN 1354-3784.
